Sodium Channel Inhibitor Compounds EP3494105A2
Summary
The European Patent Office granted patent EP3494105A2 to the Human Biomolecular Research Institute on April 15, 2026, covering compounds as inhibitors of sodium channels. The patent designates multiple European states and lists inventors CASHMAN, John, R., RYAN, Daniel, J., and OKOLOTOWICZ, Karl. IPC classifications span therapeutic compound classes including A61P9/06 (cardiovascular) and A61P25/08 (anti-epileptic), indicating potential pharmaceutical applications for sodium channel modulation.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
The European Patent Office published patent EP3494105A2 on April 15, 2026, granting exclusive rights to the Human Biomolecular Research Institute for compounds inhibiting sodium channels. The patent application, filed with IPC classifications spanning organic chemistry (C07C, C07D) and pharmaceutical compositions (A61K, A61P), designates all European Patent Convention member states including Germany, France, the United Kingdom, Italy, and the Netherlands.
Pharmaceutical companies and drug developers working on sodium channel-targeted therapeutics should review this granted patent to assess potential freedom-to-operate implications. The designated state coverage means patent protection extends across major European markets, and competitors developing similar sodium channel inhibitor compounds may need to consider licensing arrangements or design-around strategies to avoid infringement.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS
Publication EP3494105A2 Kind: A2 Apr 15, 2026
Applicants
Human Biomolecular Research Institute
Inventors
CASHMAN, John, R., RYAN, Daniel, J., OKOLOTOWICZ, Karl
IPC Classifications
C07C 217/58 20060101AFI20200406BHEP C07D 213/64 20060101ALI20200406BHEP C07D 213/65 20060101ALI20200406BHEP C07D 213/68 20060101ALI20200406BHEP A61K 31/138 20060101ALI20200406BHEP A61K 31/44 20060101ALI20200406BHEP A61K 35/12 20150101ALI20200406BHEP A61K 35/545 20150101ALI20200406BHEP A61K 45/06 20060101ALI20200406BHEP A61P 9/06 20060101ALI20200406BHEP A61P 25/08 20060101ALI20200406BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.